National healthcare spending jumped 9.7% last year, topping $4.1 trillion

National healthcare spending jumped by 9.7% in 2020, reaching an overall total of $4.1 trillion, according to new data published Wednesday in Health Affairs.

The increase amounts to about $12,530 per person in the U.S., with total growth significantly outpacing the 4.3% increase reported in 2019, the Center’s for Medicare and Medicaid Services Office of the Actuary reported. Much of this is due to the sudden 36% increase in federal spending that occurred during the height of the COVID-19 pandemic.

The substantial growth in healthcare spending was the largest since 2002 and driven by the unprecedented government response to the global pandemic,” Micah Hartman, a statistician in the CMS Office of the Actuary, and co-authors wrote in the study. “Federal spending increased rapidly in 2020 as the government increased public health spending to combat the pandemic and provided significant assistance to healthcare providers.”

Hartman et al. attributed federal healthcare spending to three specific areas: provider assistance programs such as the $122 billion included in the Provider Relief Fund along with $53 billion in the Paycheck Protection Program; increases in public health spending; and a surge in Medicaid payments following an uptick in enrollment which also coincided with additional medical assistance spending.

By comparison, total U.S. spending, excluding government-backed programs, increased by only 1.9% in 2020, declining from the 4.3% the year prior. Much of this was due to the decreased use of medical services and goods during the pandemic, the authors noted.

There will likely be pandemic-related effects seen in future healthcare expenditures, the authors explained, but they are likely to match what happened in 2020. 

“Uncertainty remains regarding how the pandemic may evolve during the winter months (given the emergence of the Omicron variant in late fall 2021), whether the pandemic plays a significant role in 2022 and beyond, and whether there are other factors that might affect future healthcare consumption decisions,” the researchers concluded. “We do know, however, that the story that unfolded in 2020 and continues today is unlike anything that has happened in the past 100 years."

Read much more from the authors here.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.